Tourette's disorder

Current Treatment Options in Neurology

Volumn 12, Issue 4, 2010, Pages 274-286

  Lyon, Gholson J ^a   Shprecher, David ^a   Coffey, Barbara ^a   Kurlan, Roger ^a  

^a OVERLOOK HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIHYPERTENSIVE AGENT; ARIPIPRAZOLE; ATOMOXETINE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; BOTULINUM TOXIN A; CABERGOLINE; CLONAZEPAM; CLONIDINE; FLUOXETINE; FLUPHENAZINE; GUANFACINE; HALOPERIDOL; METHYLPHENIDATE; OLANZAPINE; PAROXETINE; PERGOLIDE; PIMOZIDE; PLACEBO; PRAMIPEXOLE; QUETIAPINE; RISPERIDONE; ROPINIROLE; TETRABENAZINE; TOPIRAMATE; ZIPRASIDONE;

ADD ON THERAPY; AGITATION; AKATHISIA; ANESTHESIA COMPLICATION; ATTENTION DEFICIT DISORDER; BALANCE IMPAIRMENT; BEDTIME DOSAGE; BEHAVIOR THERAPY; BLEPHAROSPASM; BLOOD PRESSURE; BRAIN DEPTH STIMULATION; CERVICAL DYSTONIA; CLINICAL FEATURE; CLINICAL TRIAL; CLOSED ANGLE GLAUCOMA; COGNITION; COGNITIVE DEFECT; COGNITIVE THERAPY; DEPRESSION; DIET SUPPLEMENTATION; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPHAGIA; DYSPHORIA; EVENING DOSAGE; EXTRAPYRAMIDAL SYNDROME; FATIGUE; GILLES DE LA TOURETTE SYNDROME; HEADACHE; HEART ARRHYTHMIA; HEART RATE; HUMAN; HYPERKINESIA; HYPERPROLACTINEMIA; INJECTION SITE INFECTION; LIFESTYLE; LOW DRUG DOSE; MANIA; MOTOR NEURON DISEASE; MYOPATHY; NAUSEA; NEPHROLITHIASIS; NEUROLEPTIC MALIGNANT SYNDROME; NEUROMUSCULAR JUNCTION DISORDER; OBSESSIVE COMPULSIVE DISORDER; PARKINSON DISEASE; PARKINSONISM; PERIOPERATIVE COMPLICATION; POSTOPERATIVE COMPLICATION; QT PROLONGATION; QUANTITATIVE ANALYSIS; RECOMMENDED DRUG DOSE; RESTLESS LEGS SYNDROME; REVIEW; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; SYNCOPE; TARDIVE DYSKINESIA; TIC; TREATMENT DURATION; TREATMENT OUTCOME; VALVULAR HEART DISEASE; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 77956395162     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11940-010-0073-x     Document Type: Review

References (51)

1. Kurlan R: Diagnostic criteria for genetic studies of Tourette's syndrome. Arch Neurol 1997, 54:517-518.
2. Kurlan R, McDermott MP, Deeley C: Prevalence of tics in school children and association with placement in special education. Neurology 2001, 57:1383-1388.
3. Tourette's Syndrome Study Group: Treatment of ADHD in children with tics: A randomized controlled trial. Neurology 2002, 58:527-536.
4. Allen AJ, Kurlan RM, Gilbert DL, et al.: Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology 2005, 65:1941-1949.
5. Kompoliti K, Fan W, Leurgans S: Complementary and alternative medicine use in Gilles de la Tourette syndrome. Mov Disord 2009, 24:2015-2019.
6. Garcia-Lopez R, Perea-Milla E, Garcia CR, et al.: New therapeutic approach to Tourette Syndrome in children based on a randomized placebocontrolled double-blind phase IV study of the effectiveness and safety of magnesium and vitamin B6. Trials 2009, 10:16.
7. Boon-Yasidhi V, Kim YS, Scahill L: An open-label, prospective study of guanfacine in children with ADHD and tic disorders. J Med Assoc Thai 2005, 88 (suppl 8):S156-S162.
8. Du YS, Li HF, Vance A, et al.: Randomized doubleblind multicentre placebo-controlled clinical trial of the clonidine adhesive patch for the treatment of tic disorders. Aust N Z J Psychiatry 2008, 42:807-813.
9. King A, Harris P, Fritzell J, Kurlan R: Syncope in children with Tourette's syndrome treated with guanfacine. Mov Disord 2006, 21:419-420.
10. Horrigan JP, Barnhill LJ: Guanfacine and secondary mania in children. J Affect Disord 1999, 54:309-314.
11. Gilbert DL, Lipps TD: Tourette's syndrome. Curr Treat Options Neurol 2005, 7:211-219.
12. McCracken JT, Suddath R, Chang S, et al.: Effectiveness and tolerability of open label olanzapine in children and adolescents with Tourette syndrome. J Child Adolesc Psychopharmacol 2008, 18:501-508.
13. Stephens RJ, Bassel C, Sandor P: Olanzapine in the treatment of aggression and tics in children with Tourette's syndrome-a pilot study. J Child Adolesc Psychopharmacol 2004, 14:255-266.
14. Sallee FR, Kurlan R, Goetz CG, et al.: Ziprasidone treatment of children and adolescents with Tourette's syndrome: A pilot study. J Am Acad Child Adolesc Psychiatry 2000, 39:292-299.
15. Scahill L, Blair J, Leckman JF, Martin A: Sudden death in a patient with Tourette syndrome during a clinical trial of ziprasidone. J Psychopharmacol 2005, 19:205-206.
16. Blair J, Scahill L, State M, Martin A: Electrocardiographic changes in children and adolescents treated with ziprasidone: A prospective study. J Am Acad Child Adolesc Psychiatry 2005, 44:73-79.
17. de Jonge JL, Cath DC, van Balkom AJ: Quetiapine in patients with Tourette's disorder: An open-label, flexible-dose study. J Clin Psychiatry 2007, 68:1148-1150.
18. Mukaddes NM, Abali O: Quetiapine treatment of children and adolescents with Tourette's disorder. J Child Adolesc Psychopharmacol 2003, 13:295-299.
19. Lyon GJ, Samar S, Jummani R, et al.: Aripiprazole in children and adolescents with Tourette's disorder: An open-label safety and tolerability study. J Child Adolesc Psychopharmacol 2009, 19:623-633.
20. Budman C, Coffey BJ, Shechter R, et al.: Aripiprazole in children and adolescents with Tourette disorder with and without explosive outbursts. J Child Adolesc Psychopharmacol 2008, 18:509-515.
21. Seo WS, Sung HM, Sea HS, Bai DS: Aripiprazole treatment of children and adolescents with Tourette disorder or chronic tic disorder. J Child Adolesc Psychopharmacol 2008, 18:197-205.
22. Pringsheim T, Marras C: Pimozide for tics in Tourette's syndrome. Cochrane Database Syst Rev 2009, 2: CD006996.
23. Sallee FR, Nesbitt L, Jackson C, et al.: Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder. Am J Psychiatry 1997, 154:1057-1062.
24. Borison RL, Ang L, Chang S, et al.: New pharmacological approaches in the treatment of Tourette syndrome. Adv Neurol 1982, 35:377-382.
25. Jain S, Greene PE, Frucht SJ: Tetrabenazine therapy of pediatric hyperkinetic movement disorders. Mov Disord 2006, 21:1966-1972.
26. Kenney C, Hunter CB, Mejia NI, Jankovic J: Tetrabenazine in the treatment of Tourette syndrome. J Pediatr Neurol 2007, 5:9-13.
27. Ondo WG, Jong D, Davis A: Comparison of weight gain in treatments for Tourette syndrome: Tetrabenazine versus neuroleptic drugs. J Child Neurol 2008, 23:435-437.
28. Porta M, Sassi M, Cavallazzi M, et al.: Tourette's syndrome and role of tetrabenazine: Review and personal experience. Clin Drug Investig 2008, 28:443-459. This is the largest long-term follow-up series on tetrabenazine for TD. This paper also reviews prior literature.
29. Kenney C, Hunter C, Jankovic J: Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord 2007, 22:193-197.
30. Goetz CG: Clonidine and clonazepam in Tourette syndrome. Adv Neurol 1992, 58:245-251.
31. Aksent'ev SB, Borisova NP, Levinski MV, Kryzhanovski GN: Complex use of benzodiazepines, lithium salts and haloperidol in the treatment of obsessive movements and tics of different origin [in Russian]. Zh Nevropatol Psikhiatr Im SS Korsakova 1987, 87:432-437.
32. Merikangas JR, Merikangas KR, Kopp U, Hanin I: Blood choline and response to clonazepam and haloperidol in Tourette's syndrome. Acta Psychiatr Scand 1985, 72:395-399.
33. Gonce M, Barbeau A: Seven cases of Gilles de la Tourette's syndrome: Partial relief with clonazepam: A pilot study. Can J Neurol Sci 1977, 4:279-283.
34. Simpson DM, Blitzer A, Brashear A, et al.: Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008, 70:1699-1706. This is an evidence-based review and guidelines regarding the use of botulinum toxin in treating TD and other movement disorders
35. Kwak CH, Hanna PA, Jankovic J: Botulinum toxin in the treatment of tics. Arch Neurol 2000, 57:1190-1193.
36. Servello D, Porta M, Sassi M, et al.: Deep brain stimulation in 18 patients with severe Gilles de la Tourette syndrome refractory to treatment: The surgery and stimulation. J Neurol Neurosurg Psychiatry 2008, 79:136-142.
37. Maciunas RJ, Maddux BN, Riley DE, et al.: Prospective randomized double-blind trial of bilateral thalamic deep brain stimulation in adults with Tourette syndrome. J Neurosurg 2007, 107:1004-1014.
38. Mink JW: Clinical review of DBS for Tourette syndrome. Front Biosci (Elite Ed) 2009, 1:72-76.
39. Deckersbach T, Rauch S, Buhlmann U, Wilhelm S: Habit reversal versus supportive psychotherapy in Tourette's disorder: A randomized controlled trial and predictors of treatment response. Behav Res Ther 2006, 44:1079-1090.
40. Carr JE, Chong IM: Habit reversal treatment of tic disorders: A methodological critique of the literature. Behav Modif 2005, 29:858-875.
41. Piacentini J: Behavioral treatment of Tourette's disorder across the lifespan: The NIMH CBITS studies. Presented at the 43rd Annual Meeting of the Association for Behavioral and Cognitive Therapies. New York; November 19-22, 2009. The results of this trial are eagerly awaited; the results presented at meetings have been positive.
42. Fernández-Jaén A, Fernández-Mayoralas DM, Munoz-Jareno N, Calleja-Pérez B: An open-label, prospective study of levetiracetam in children and adolescents with Tourette syndrome. Eur J Paediatr Neurol 2009, 13:541-545.
43. Hedderick EF, Morris CM, Singer HS: Double-blind, crossover study of clonidine and levetiracetam in Tourette syndrome. Pediatr Neurol 2009, 40:420-425.
44. Smith-Hicks CL, Bridges DD, Paynter NP, Singer HS: A double blind randomized placebo control trial of levetiracetam in Tourette syndrome. Mov Disord 2007, 22:1764-1770.
45. Singer HS, Wendlandt J, Krieger M, et al.: Baclofen treatment in Tourette syndrome: A double-blind, placebo-controlled, crossover trial. Neurology 2001, 56:599-604.
46. Singer HS, Morris C, Grados M: Glutamatergic modulatory therapy for Tourette syndrome. Med Hypotheses 2010, 74(5):862-867.
47. Jankovic J, Jimenez-Shahed J, Brown LW: A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. J Neurol Neurosurg Psychiatry 2010, 81:70-73.
48. Kuo SH, Jimenez-Shahed J: Topiramate in treatment of Tourette syndrome. Clin Neuropharmacol 2010, 33:32-34.
49. Anca MH, Giladi N, Korczyn AD: Ropinirole in Gilles de la Tourette syndrome. Neurology 2004, 62:1626-1627.
50. Huang XP, Steloa V, Yadav PN, et al.: Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine(2B) receptor agonists: Implications for drug safety assessment. Mol Pharmacol 2009, 76:710-722.
51. Leckman JF, Zhang H, Vitale A, et al.: Course of tic severity in Tourette syndrome: The first two decades. Pediatrics 1998, 102:14-19.